Theragnostic System for the Directed Diffusion of Therapeutic and Image Agents to Cancerous Cells - Banco de Patentes
List of Patents
Back Theragnostic System for the Directed Diffusion of Therapeutic and Image Agents to Cancerous Cells
Theragnostic System for the Directed Diffusion of Therapeutic and Image Agents to Cancerous Cells
Intravenous administration is the most frequently used route for parenteral cancer drug delivery. However, it is certain that for some types of highly focalized cancers, this way of chemotherapy administration can lead to serious toxicity-related side effects, which drastically limits the dosage and therefore hinders the efficacy of the treatment. In this context, the incorporation of a biologically active molecule over a pharmaceutical vehicle can facilitate selective diffusion to cancer cells, minimizing side effects. This is particularly noticeable when two specific targets are matched:
- intratumor administration instead of parenteral administration.
- incorporation of a targeting molecule to the pharmaceutical vehicle to ensure specific interactions with tumor cell membrane receptors.
At this point, nanoparticles of some porous materials (e.g., silica and covalent organic frameworks) show huge potential for drug delivery. Unfortunately, the biomedical use of nanoparticles is usually hindered by their low stability under physiological conditions, high immunogenicity, low specificity for cancer cells and low biodegradability.
The presented invention comprises a theragnostic system that aims to solve the toxicity problems generated by intravenous administration of cytotoxic drugs in prostate cancer treatment (chemotherapy). The invention is currently in preclinical phase with good prognosis to advance into clinical phase I in 2021.
Allows selective killing of cancer cells, lower dosage and toxicity with bigger therapeutic effect and accurate cancer cell tracking by PET
Priority Number (SPTO): P201931015
Priority Date: 20/11/2019
Cristina Alemany Làzaro
I2T - Office for the Promotion of Research, Innovation and Technology Transfer
T: +34 963 877 409